Hosted on MSN8d
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts
Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%. Meanwhile, the ...
FDA approves first non-addictive pain medication
The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to ...
Vertex Pharmaceuticals price target raised to $550 from $535 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $535 and keeps a Buy rating on the shares after ...
FDA Approves Non-Opioid Painkiller With No Addiction Risk
The Food and Drug Administration approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid ...
Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
Yahoo Finance2d
Vertex Pharmaceuticals Incorporated (VRTX)
Therefore, it is wise to be aware of the facts that can impact ... Get prepared with the key expectations. BOSTON, January 27, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report ...